Merck’s Japan unit files for approval of oral coronavirus treatment

Merck & Co.’s new antiviral medication molnupiravir
December 3, 2021
MSD K.K., a subsidiary of U.S. pharmaceutical company Merck & Co., filed an application for approval of the oral coronavirus treatment molnupiravir to the Health, Labor and Welfare Ministry on Friday.
If approved, it will be the first drug to be used in Japan for the treatment of the novel coronavirus.
The government wants the drug to be available for practical use by the end of this year.
It is said that the risk of serious illness is reduced if people with mild symptoms take the antiviral drug early in the course of the disease. In clinical trials, the drug was found to be effective in reducing the risk of serious illness by 30%, according to Merck.
The treatment has already been approved in Britain.
Japan has agreed to receive a supply of 1.6 million doses, on the assumption that the regulatory authority will swiftly approve the drug.
"Society" POPULAR ARTICLE
-
World War II Battleship Yamato Was Outdated From the Start; Unable to Compete With Newly Developed Warplanes
-
Nankai Trough Megaquake Estimated Death Toll Lowered, Tsunami-hit Area Increased in Govt Report
-
Estimated Magnitude 5 Earthquake Hits Nagano Pref. ; No Tsunami Warning Issued (UPDATE 2)
-
Cherry Blossoms Reach Full Bloom in Tokyo; Ueno Park Draws Many Viewers
-
Cherry Blossoms Officially in Bloom in Tokyo, Beating Last Year’s Date by 5 Days
JN ACCESS RANKING